María Dolores Girón González

Prof. María Dolores Girón González

University of Granada, Spain
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2000 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
NNN. Nieto
N. Nieto
MLM Isabel Torres López
M Isabel Torres López
MFM.I. Fernández
M.I. Fernández
María Dolores Girón GonzálezMaría Dolores Girón González
María Dolores Girón González
ARA. Ríos
A. Ríos
AGAngel Gil
Angel Gil

5 May 2009 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
AMAlejandro Méndez-Ardoy
Alejandro Méndez-Ardoy
MGMarta Gómez-García
Marta Gómez-García
CMCarmen Ortiz Mellet
Carmen Ortiz Mellet
NSNatalia Sevillano
Natalia Sevillano
María Dolores Girón GonzálezMaría Dolores Girón González
María Dolores Girón González
JFJosé M. García Fernández
José M. García Fernández
Gene delivery systems based on the β-cyclodextrin scaffold have been synthesized by combining the copper(I)-catalyzed azide-alkyne coupling (“click chemistry”) and an efficient acylation method of the secondary hydroxyls; molecular flexibility, charge density and hydrophobic-hydrophilic balance are critical parameters that can be fine-tuned by the click approach.

1 October 2009 in Clinical Nutrition
Verified
Journal Article
Closed access
María Dolores Girón GonzálezMaría Dolores Girón González
María Dolores Girón González
NSNatalia Sevillano
Natalia Sevillano
Rafael SaltoRafael Salto
Rafael Salto
ABAli Haidour Benamin
Ali Haidour Benamin
MMManuel Manzano
Manuel Manzano
JLJosé M. López-Pedrosa
José M. López-Pedrosa

6 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
María Dolores Girón GonzálezMaría Dolores Girón González
María Dolores Girón González
JVJose D Vílchez
Jose D Vílchez
SSSathyavageeswaran Shreeram
Sathyavageeswaran Shreeram
Rafael SaltoRafael Salto
Rafael Salto
MMManuel Manzano
Manuel Manzano
JLJose M López-Pedrosa
Jose M López-Pedrosa
Dexamethasone-induced muscle atrophy is due to an increase in protein breakdown and a decrease in protein synthesis, associated with an over-stimulation of the autophagy-lysosomal pathway. These effects are mediated by alterations in IGF-1 and PI3K/Akt signaling. In this study, we have investigated the effects of β-Hydroxy-β-methylbutyrate (HMB) on the regulation of autophagy and proteosomal systems. Rats were treated during 21 days with dexamethasone as a model of muscle atrophy. Co-administration of HMB attenuated the effects promoted by dexamethasone. HMB ameliorated the loss in body weight, lean mass and the reduction of the muscle fiber cross-sectional area (shrinkage) in gastrocnemius muscle. Consequently, HMB produced an improvement in muscle strength in the dexamethasone-treated rats. To elucidate the molecular mechanisms responsible for these effects, rat L6 myotubes were used. In these cells, HMB significantly attenuated lysosomal proteolysis induced by dexamethasone by normalizing the changes observed in autophagosome formation, LC3 II, p62 and Bnip3 expression after dexamethasone treatment. HMB effects were mediated by an increase in FoxO3a phosphorylation and concomitant decrease in FoxO transcriptional activity. The HMB effect was due to the restoration of Akt signaling diminished by dexamethasone treatment. Moreover, HMB was also involved in the regulation of the activity of ubiquitin and expression of MurF1 and Atrogin-1, components of the proteasome system that are activated or up-regulated by dexamethasone. In conclusion, in vivo and in vitro studies suggest that HMB exerts protective effects against dexamethasone-induced muscle atrophy by normalizing the Akt/FoxO axis that controls autophagy and ubiquitin proteolysis.

12 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Rafael SaltoRafael Salto
Rafael Salto
DVDámaso Vílchez
Dámaso Vílchez
María Dolores Girón GonzálezMaría Dolores Girón González
María Dolores Girón González
ECElena Cabrera
Elena Cabrera
NCNefertiti Campos
Nefertiti Campos
JLJose M. López-Pedrosa
Jose M. López-Pedrosa
β-Hydroxy-β-methylbutyrate (HMB) has been shown to enhance cell survival, differentiation and protein turnover in muscle, mainly activating phosphoinositide-3-kinase/protein kinase B (PI3K/Akt) and mitogen-activated protein kinases/ extracellular-signal-regulated kinases (MAPK/ERK) signaling pathways. Since these two pathways are related to neuronal survival and differentiation, in this study, we have investigated the neurotrophic effects of HMB in mouse neuroblastoma Neuro2a cells. In Neuro2a cells, HMB promotes differentiation to neurites independent from any effects on proliferation. These effects are mediated by activation of both the PI3K/Akt and the extracellular-signal-regulated kinases (ERK1/2) signaling as demonstrated by the use of specific inhibitors of these two pathways. As myocyte-enhancer factor 2 (MEF2) family of transcription factors are involved in neuronal survival and plasticity, the transcriptional activity and protein levels of MEF2 were also evaluated. HMB promoted MEF2-dependent transcriptional activity mediated by the activation of Akt and ERK1/2 pathways. Furthermore, HMB increases the expression of brain glucose transporters 1 (GLUT1) and 3 (GLUT3), and mTOR phosphorylation, which translates in a higher protein synthesis in Neuro2a cells. Furthermore, Torin1 and rapamycin effects on MEF2 transcriptional activity and HMB-dependent neurite outgrowth support that HMB acts through mTORC2. Together, these findings provide clear evidence to support an important role of HMB in neurite outgrowth.

14 May 2015 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
María Dolores Girón GonzálezMaría Dolores Girón González
María Dolores Girón González
DVDámaso Vílchez
Dámaso Vílchez
Rafael SaltoRafael Salto
Rafael Salto
MMManuel Manzano
Manuel Manzano
NSNatalia Sevillano
Natalia Sevillano
JLJosé M. López-Pedrosa
José M. López-Pedrosa
Background L-Leu and its metabolite β-hydroxy-β-methylbutyrate (HMB) stimulate muscle protein synthesis enhancing the phosphorylation of proteins that regulate anabolic signalling pathways. Alterations in these pathways are observed in many catabolic diseases, and HMB and L-Leu have proven their anabolic effects in in vivo and in vitro models. The aim of this study was to compare the anabolic effects of L-Leu and HMB in myotubes grown in the absence of any catabolic stimuli. Methods Studies were conducted in vitro using rat L6 myotubes under normal growth conditions (non-involving L-Leu-deprived conditions). Protein synthesis and mechanistic target of rapamycin signalling pathway were determined. Results Only HMB was able to increase protein synthesis through a mechanism that involves the phosphorylation of the mechanistic target of rapamycin as well as its downstream elements, pS6 kinase, 4E binding protein-1, and eIF4E. HMB was significantly more effective than L-Leu in promoting these effects through an activation of protein kinase B/Akt. Because the conversion of L-Leu to HMB is limited in muscle, L6 cells were transfected with a plasmid that codes for α-keto isocaproate dioxygenase, the key enzyme involved in the catabolic conversion of α-keto isocaproate into HMB. In these transfected cells, L-Leu was able to promote protein synthesis and mechanistic target of rapamycin regulated pathway activation equally to HMB. Additionally, these effects of leucine were reverted to a normal state by mesotrione, a specific inhibitor of α-keto isocaproate dioxygenase. Conclusion Our results suggest that HMB is an active L-Leu metabolite able to maximize protein synthesis in skeletal muscle under conditions, in which no amino acid deprivation occurred. It may be proposed that supplementation with HMB may be very useful to stimulate protein synthesis in wasting conditions associated with chronic diseases, such as cancer or chronic heart failure.